Literature DB >> 17622838

Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.

Bonaventura Clotet1, Eugenia Negredo, Pierre Marie Girard, Mike Youle, Dietmar Neubacher.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622838     DOI: 10.1097/QAI.0b013e318061b76e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  1 in total

1.  Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.

Authors:  P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.